CEO Eliane Schutte shared how Xeltis restorative devices can help combine clinical needs with a patient-centric approach in cardiovascular treatment. Speaking today at LSX World Congress 2022 in London, Eliane explained how the most advanced [...]

Preliminary results from a clinical trial of Xeltis’ restorative hemodialysis access graft, aXess, showed very promising early puncturing, functional patency and safety data. The data, from the ongoing first-in-human aXess trial, will be presented [...]

Renal Interventions dedicated a feature article to arteriovenous grafts (AVG) for hemodialysis access, in which Xeltis’ restorative AVG graft aXess is prominently discussed among promising novel devices in vascular access. According to RI, aXess [...]

Xeltis’ devices are the first living applications of supramolecular materials for cardiovascular restoration in patients. An article published in peer-reviewed journal Materials Today showcases how Xeltis implanted the first clinical devices made of supramolecular biomaterials [...]

Results from preclinical trials of Xeltis restorative coronary artery bypass graft XABG showed superior performance of the Xeltis graft compared to harvested saphenous veins at one year. The data have been presented at the [...]

The aXess clinical study of Xeltis restorative access graft for hemodialysis is proceeding at full speed, announced today Xeltis CEO Eliane Schutte at Biocapital Europe. Over 350 successful dialysis sessions have been completed in [...]

Matteo Tozzi, MD, vascular surgeon and professor of vascular surgery at Università dell’Insubria in Italy, and Frans L. Moll, MD, PhD, professor emeritus of vascular surgery at the University Medical Center Utrecht in The Netherlands, provided insights on the progress of [...]

Xeltis will receive €15 million in funding from the European Innovation Council Accelerator (EIC) set up by the European Commission. The EIC funding comprises €2.5 millions in grants and up to €12.5 millions in [...]

Xeltis has initiated the clinical trial for aXess, the first-ever restorative synthetic haemodialysis access graft. Several patients with kidney failure or advanced kidney disease requiring dialysis have already been successfully implanted as part of [...]

The Xeltis Executive Team has been joined by seasoned medtech business leader David Mester as Vice-President, Business Lead, Valve. David has over 30 years of experience in structural heart devices and dedicated his career [...]